PDS Planning Inc Raises Stock Position in Becton, Dickinson and Company (NYSE:BDX)

PDS Planning Inc lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 23.8% during the second quarter, HoldingsChannel.com reports. The fund owned 1,182 shares of the medical instruments supplier’s stock after buying an additional 227 shares during the quarter. PDS Planning Inc’s holdings in Becton, Dickinson and were worth $291,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Icapital Wealth LLC acquired a new stake in Becton, Dickinson and in the first quarter valued at approximately $31,000. Disciplined Investments LLC acquired a new position in Becton, Dickinson and during the first quarter valued at $32,000. Rosenberg Matthew Hamilton increased its holdings in Becton, Dickinson and by 61.5% in the first quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 48 shares in the last quarter. Core Alternative Capital increased its holdings in Becton, Dickinson and by 688.2% in the first quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 117 shares in the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new position in Becton, Dickinson and in the fourth quarter valued at $38,000. 86.74% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Trading Down 0.3 %

NYSE BDX opened at $237.19 on Friday. The company’s fifty day simple moving average is $252.37 and its 200-day simple moving average is $253.93. Becton, Dickinson and Company has a 52 week low of $231.46 and a 52 week high of $280.62. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.58. The stock has a market cap of $67.65 billion, a P/E ratio of 40.89, a PEG ratio of 3.12 and a beta of 0.57.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The business had revenue of $4.64 billion for the quarter, compared to analysts’ expectations of $4.47 billion. During the same period in the previous year, the company posted $2.74 earnings per share. The business’s revenue for the quarter was down 5.1% compared to the same quarter last year. Equities research analysts predict that Becton, Dickinson and Company will post 11.31 EPS for the current fiscal year.

Becton, Dickinson and Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 9th will be given a dividend of $0.87 per share. The ex-dividend date is Thursday, September 8th. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.47%. Becton, Dickinson and’s payout ratio is currently 60.00%.

Insider Transactions at Becton, Dickinson and

In related news, CEO Thomas E. Polen, Jr. sold 9,500 shares of Becton, Dickinson and stock in a transaction on Monday, August 15th. The shares were sold at an average price of $265.13, for a total value of $2,518,735.00. Following the completion of the sale, the chief executive officer now owns 28,878 shares in the company, valued at $7,656,424.14. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Thomas E. Polen, Jr. sold 9,500 shares of Becton, Dickinson and stock in a transaction on Monday, August 15th. The shares were sold at an average price of $265.13, for a total value of $2,518,735.00. Following the completion of the sale, the chief executive officer now owns 28,878 shares in the company, valued at $7,656,424.14. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Hickey sold 475 shares of Becton, Dickinson and stock in a transaction on Monday, August 15th. The stock was sold at an average price of $265.00, for a total transaction of $125,875.00. Following the completion of the sale, the executive vice president now owns 3,331 shares of the company’s stock, valued at approximately $882,715. The disclosure for this sale can be found here. Over the last three months, insiders have sold 19,160 shares of company stock valued at $5,036,751. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Morgan Stanley cut their target price on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a research note on Friday, July 15th. Citigroup lowered shares of Becton, Dickinson and from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $265.00 to $235.00 in a report on Monday, July 11th. Wells Fargo & Company raised shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 target price on the stock in a research note on Friday, June 24th. Stifel Nicolaus dropped their price objective on shares of Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. Finally, The Goldman Sachs Group increased their target price on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a research report on Tuesday, August 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $277.63.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Recommended Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.